how were glp 1 drugs discovered GLP-1 Receptor Agonists Evolved from Diabetes Treatments to Weight Loss Treatments History of GLP-1 Medications -

Beatriz Fernandez-Fernandez, Department of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain

Survey data demonstrate people taking GLP-1RAs semaglutide and tirzepatide report reduced sedative and stimulative effects of alcohol 18

GLP-1MK-801 versus semaglutide To further scrutinize the translational potential of GLP-1MK-801, we benchmarked it against semaglutide, a pharmacokinetically optimized GLP-1 receptor agonist approved for treatment of obesity and clinically available as a once-weekly injectable 33

Despite these promising developments, GLP-1RAs are associated with side effects and high costs, contributing to variability in patient access

insulin glargine in high cardiovascular-risk type 2 diabetes), tirzepatide was associated with a reduction in albuminuria whereas insulin glargine showed an increase, supporting the hypothesis that greater weight loss and metabolic improvements can translate into larger albuminuria reductions [107]

The consistency of findings across multiple retrospective cohorts and data sources provides a compelling signal of efficacy on clinical endpoints, justifying a shift in research focus: the field now needs adequately powered phase 3 randomized controlled trials to validate these preliminary findings [58], define optimal treatment strategies such as dosing and treatment duration, and establish the role of GLP-1 RAs in both acute and long-term management of IIH